BIOMARKER:

ALK negative

Entrez ID:

Related biomarkers:

‹

›

ALK negative ALK negative	Non Small Cell Lung Cancer NSCLC	ALK negative ALK negative	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
ALK negative ALK negative	Mantle Cell Lymphoma Mantle Cell Lymphoma	ALK negative ALK negative	Mantle Cell Lymphoma Mantle Cell Lymphoma	brentuximab vedotin Sensitive: A2 - Guideline	brentuximab vedotin Sensitive: A2 - Guideline
ALK negative ALK negative	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	ALK negative ALK negative	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	brentuximab vedotin Sensitive: B - Late Trials	brentuximab vedotin Sensitive: B - Late Trials
ALK negative ALK negative	Non-Hodgkin’s Lymphoma NHL	ALK negative ALK negative	Non-Hodgkin’s Lymphoma NHL	brentuximab vedotin Sensitive: B - Late Trials	brentuximab vedotin Sensitive: B - Late Trials
ALK negative ALK negative	Non Small Cell Lung Cancer NSCLC	ALK negative ALK negative	Non Small Cell Lung Cancer NSCLC	pembrolizumab + atezolizumab Sensitive: B - Late Trials	pembrolizumab + atezolizumab Sensitive: B - Late Trials
ALK negative ALK negative	Non-Hodgkin’s Lymphoma NHL	ALK negative ALK negative	Non-Hodgkin’s Lymphoma NHL	etoposide IV Sensitive: C3 – Early Trials	etoposide IV Sensitive: C3 – Early Trials
ALK negative ALK negative	Non Small Cell Lung Cancer NSCLC	ALK negative ALK negative	Non Small Cell Lung Cancer NSCLC	sintilimab Sensitive: C3 – Early Trials	sintilimab Sensitive: C3 – Early Trials